- Home
- STXS vs IPHA Comparison
STXS vs IPHA Comparison
Compare STXS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STXS
- IPHA
- Stock Information
- Founded
- STXS 1990
- IPHA 1999
- Country
- STXS United States
- IPHA France
- Employees
- STXS N/A
- IPHA N/A
- Industry
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- STXS Health Care
- IPHA Health Care
- Exchange
- STXS Nasdaq
- IPHA Nasdaq
- Market Cap
- STXS 151.3M
- IPHA 160.1M
- IPO Year
- STXS 2004
- IPHA 2019
- Fundamental
- Price
- STXS $2.29
- IPHA $1.92
- Analyst Decision
- STXS
- IPHA Strong Buy
- Analyst Count
- STXS 0
- IPHA 1
- Target Price
- STXS N/A
- IPHA $11.00
- AVG Volume (30 Days)
- STXS 337.3K
- IPHA 8.6K
- Earning Date
- STXS 08-11-2025
- IPHA 09-11-2025
- Dividend Yield
- STXS N/A
- IPHA N/A
- EPS Growth
- STXS N/A
- IPHA N/A
- EPS
- STXS N/A
- IPHA N/A
- Revenue
- STXS $27,510,000.00
- IPHA $20,831,349.00
- Revenue This Year
- STXS $25.90
- IPHA $209.83
- Revenue Next Year
- STXS $60.57
- IPHA $83.15
- P/E Ratio
- STXS N/A
- IPHA N/A
- Revenue Growth
- STXS 1.50
- IPHA N/A
- 52 Week Low
- STXS $1.54
- IPHA $1.29
- 52 Week High
- STXS $2.72
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- STXS 68.10
- IPHA 54.82
- Support Level
- STXS $2.10
- IPHA $1.71
- Resistance Level
- STXS $2.32
- IPHA $1.84
- Average True Range (ATR)
- STXS 0.12
- IPHA 0.07
- MACD
- STXS 0.03
- IPHA 0.02
- Stochastic Oscillator
- STXS 98.81
- IPHA 78.57
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.